Cipla receives warning letter from USFDA for Goa manufacturing facility

26 Feb 2020 Evaluate

Cipla has received a warning letter from the United States Food and Drug Administration (USFDA) for its Goa manufacturing facility. The USFDA had conducted inspection from September 16, 2019 to September 27, 2019.The company remains committed to maintain the highest standards of compliance and will work closely with the agency to comprehensively address all the observations.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.


Cipla Share Price

1508.10 8.00 (0.53%)
02-Jan-2026 14:44 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1724.95
Dr. Reddys Lab 1252.65
Cipla 1508.10
Zydus Lifesciences 915.45
Lupin 2104.95
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×